The EZH2 Paradox in Triple-Negative Breast Cancer: Both Arms Confirmed in GSE25066 and Resolution via Waddington Attractor Geometry

Zenodo (CERN European Organization for Nuclear Research) 2026 Preprint Open access

Read full text
Authors: Eric Robert Lawson
DOI: 10.5281/zenodo.18891318
Cited by: 2

Abstract

High EZH2 expression in triple-negative breast cancer (TNBC) simultaneously predicts better pathological complete response (pCR) to neoadjuvant chemotherapy and worse distant recurrence-free survival (DRFS) — a clinical paradox. Both arms were confirmed together in GSE25066 (n=508 TNBC patients treated with neoadjuvant chemotherapy): pCR p

Fields of Study & Subjects

Genomics and Chromatin Dynamics Epigenetics and DNA Methylation Breast Cancer Treatment Studies

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
6 March 2026
Language
EN
Document type
Preprint